Connect with us

Breaking News

New gene therapy slows progression of Huntington’s disease by 75%

Published

on

Read more on post .

image

A new gene therapy has slowed the progression of Huntington’s disease by as much as 75%.

Known as AMT-130, it is delivered via brain surgery, and a single dose is expected to last someone’s whole life.

“This result changes everything,” said principal investigator Professor Ed Wild.

Thirty-year-old Jack May-Davis, who took part in trials, said the results were “astonishing”, leaving him “lost for words”.

Huntington’s is a neurodegenerative disease which gets worse over time and has no cure, affecting thinking, movement and mood. About 8,000 people in the UK suffer from it.

While the disease typically lasts for about 20 years, loss of function can begin quite quickly.

In a trial, 12 patients were given the highest dose of AMT-130. Researchers reported they experienced 75% less disease progression after 36 months compared to a group of people with Huntington’s who were not given the treatment.

AMT-130 works by permanently introducing new functional DNA into a person’s cells, researchers said.

“On the basis of these results, it seems likely AMT-130 will be the first licensed treatment to slow Huntington’s disease, which is truly world-changing stuff,” said Prof Wild, from the University College London (UCL) Huntington’s Disease Centre.

“My patients in the trial are stable over time in a way I’m not used to seeing in Huntington’s disease.”

One of them, he added, was medically retired but has been able to return to work.

Absolutely breathtaking’ findings

Prof Wild told Sky News presenter Jayne Secker the 75% slowing was “absolutely breathtaking… that could be years or decades of top quality life or even complete disease freedom if we treat early enough”.

He added: “There are undoubtedly patients in this trial who would have been in wheelchairs by now, who are still able to walk and are independent.

“And if we can bring this therapy to as many people as possible, the impact on families who are struggling with this condition for themselves and their children will be immense.”

Could symptoms be prevented from occurring?

Professor Sarah Tabrizi, also from UCL, said AMT-130 had the potential to “preserve daily function”, keep people in work longer, and “meaningfully slow disease progression”.

She told Jayne Secker that those in the trial had “very early symptomatic disease”, but she hopes that the therapy in future will be given to people with “stage zero and stage one disease who have no symptoms at all”.

“And that one day we might be able to prevent the symptoms occurring, which would be a true prevention in people who carry the Huntington’s gene but don’t yet have symptoms. And that’s the goal of all of our research currently.”

Read more:
Boris Becker ‘shocked’ by drug use in UK prison
Man arrested in connection with airports cyber attack

Jack May-Davis, from Sussex, discovered he was carrying the Huntington’s gene when he was 19.

Two family members, including his father, died from Huntington’s.

“It is just amazing,” he said. “When I started participating in trials I never thought something would be developed in a time frame that might actually be useful for me.

“This feels like a huge moment that will mean so much to families who carry the Huntington’s gene.”

Professor Mike Hanna, director of the UCL Queen Square Institute of Neurology, said: “These findings point to a new chapter in gene therapy development for Huntington’s disease, and have clear relevance for other devastating neurodegenerative disorders.”

Cath Staney, chief executive of the Huntington’s Disease Association, said: “This is a significant breakthrough, and I am sure it will bring hope to anyone affected by Huntington’s disease.

“This trial shows an astonishing 75% slowing of progression in the disease.

“That is remarkable and will bring much-needed optimism to the Huntington’s disease community.”

Breaking News

No one-off measures in next year’s Budget – Donohoe

Published

on

Read more on post.

The Minster for Finance has insisted there will be no repeat of last year’s once-off cost of living measures, but other permanent supports will be put in place in next month’s Budget.

Speaking at the Oireachtas Budgetary Oversight Committee, Paschal Donohoe said inflation has normalised, although the Government understands that prices have risen.

“Government is fully aware of the impact inflation has had on businesses and households throughout the country over recent years,” he said.

“Inflation has now returned to normal rates, but we are acutely conscious that price levels have risen in recent years, especially for necessities such as food. In this Budget, we will provide cost of living supports that are sustainable and permanent.”

Mr Donohoe told the Committee the economy is resilient, the public finances are in good shape and Modified Domestic Demand which measures activity in the domestic economy grew 4% in the first half of 2025.

However, he said it is not a time for complacency and the rate of growth of current spending has to be moderated. He also spoke the danger of over reliance on corporation tax receipts.

“Ireland must remain a top destination for multinational firms. These corporation tax revenues helped fund Government’s extraordinary response to the pandemic and the cost of living challenge,” he said.

“Nonetheless, I have warned on many occasions about the risks of overreliance on corporation tax. A highly concentrated tax base presents an inherent risk to sustainable public finances.

“Ten companies account for well over half of all corporate tax receipts. A negative shock to these companies would also negatively impact VAT and income tax revenues.”

Mr Donohoe said Budget 2026 is coming at a time of great uncertainty and the disruption of internationally settled trade rules will damage Ireland’s economic growth.

He said, however, the economy is fundamentally resilient.

Budget 2026 will be announced in the Dáil on 7 October by the Mr Donohoe and the Minister for Public Expenditure, Infrastructure, Public Services and Reform, Jack Chambers.

Continue Reading

Breaking News

West Bank locals report ongoing Israeli settler expansion

Published

on

Read more on post.

Europe Editor Tony Connelly and cameraman Bram Verbeke report from Turmus Ayya and al-Mughayyir in the West Bank where locals report the continued expansion of Israel settlements and the destruction of local farms.


The ancient olive groves of the West Bank, the ideal retirement for a Palestinian-US citizen returning from California.

But, since 7 October, Israeli settlers from across the valley have intimidated Yasser Alkam from accessing his father’s legacy in Turmus Ayya.

Mr Alkam said he legally owns the land, adding that he has the paperwork and a title document for it.

However, in one incident, he said a gun was drawn on him, during which he was told “leave or else”.

Yasser Alkam stands on a sandy hill in the West Bank.
Yasser Alkam said two tents have been set up nearby

The legal rights count for little, as settlers seizing or destroying the olive groves are backed by the Israeli military, who mount nightly patrols around Mr Alkam’s neighbourhood and appear by day to support the expansion towards his town.

He noted that, two weeks ago, there was “one single tent” nearby, but added that currently there are two.

“One on the right side of the street and one on the left side of the street,” he said.

“It continues to spread out closer and closer to the town,” he added.

A settler witnessed the RTÉ News interview with Mr Alkam, and launched a drone that duly appeared and hovers above the interaction.


Watch: Drone hovers overhead while RTÉ News interviews Palestinian farmer in West Bank


Mr Alkum’s olive trees remain intact for now, but another village, 6km away, has not been so fortunate – as fresh settler outposts have sprung up.

There are two new and illegal outposts on the hills near the village.

But the real dispossession has happened in the valley, where hundreds of hectares of land were uprooted by bulldozers.

Over 10,000 olive trees were destroyed and taken away, according to the locals.

A bulldozer pictured in the West Bank.
Hundreds of hectares of land have been uprooted by bulldozers

Locals say a confrontation with settlers last month triggered an assault by two busloads of military and settlers equipped with bulldozers.

Deputy head of the al-Mughayyir municipality Marzouq Abu Naem said the destroyed olive trees “would have provided 5,000 gallons of olive oil, each gallon worth $150”.

“All this income has gone, just like the olive trees themselves,” he said.

Deputy head of municipality Marzouq Abu Naem standing in the West Bank.
Marzouq Abu Naem said people ‘collapsed in grief’ when they saw the trees were gone

Mr Naem said the trees “represented our history, our culture”.

He added that people “collapsed in grief” when they saw the trees were gone.

Not long after RTÉ News visited, locals said settlers attacked again.

A local man was wounded and he later died of his injuries.

The funeral was held today.

Clashes between settlers and Palestinians have grown ever more deadly as Israel defiantly shrugs off international outrage over Gaza and turns its attention on the parched hills of the West Bank.

Continue Reading

Breaking News

‘Nightmare bacteria’ cases rising in the US

Published

on

Read more on post .

Infection rates from drug-resistant “nightmare bacteria” rose by 70% in the US, according to a new report. 

The increase is driven by a difficult-to-treat gene called NDM, say researchers from the American Centers for Disease Control and Prevention.

Only two antibiotics work to treat it – and the drugs are expensive and have to be administered intraveneously.

Bacteria with the gene were once considered exotic, linked to a small number of patients who received medical care overseas, and though the numbers are still small, the rate of US cases jumped more than fivefold in recent years, the researchers reported.

“The rise of NDMs in the US is a grave danger and very worrisome,” said David Weiss, an infectious diseases researcher at Emory University in Atlanta, Georgia.

The report took data from 29 states. It counted 4,341 cases of carbapenem-resistant bacterial infections from those states in 2023, with 1,831 of them the NDM variety.

Pic: AP
Image:
Pic: AP

The rate of carbapenem-resistant infections rose from just under 2 per 100,000 people in 2019 to more than 3 per 100,000 in 2023 – an increase of 69%. But the rate of NDM cases rose from around 0.25 to about 1.35 – an increase of 460%, the authors said.

More from Science, Climate & Tech

In recent years, the CDC has drawn attention to “nightmare bacteria” resistant to a wide range of antibiotics.

Carbapenems are a class of antibiotics considered a last resort for treatment of serious infections.

The researchers did not say how many of the infected people died.

It’s likely many people are unrecognised carriers of the drug-resistant bacteria, which could lead to community spread, the CDC scientists warned.

It is feared that infections long considered routine and easy to combat – like urinary tract infections – could become harder to treat, said Dr Maroya Walters, one of the report’s authors.

Read more from Sky News:
How a tractor, lifeboat and ambulance crew saved my life
The health claims made by Trump

Antimicrobial resistance occurs when germs such as bacteria and fungi gain the power to fight off the drugs designed to kill them.

The misuse of antibiotics was a big reason for the rise – unfinished or unnecessary prescriptions that didn’t kill the germs made them stronger.

‘Huge surge’

A researcher not involved in the study said the increase is probably related to the COVID-19 pandemic.

“We know that there was a huge surge in antibiotic use during the pandemic, so this likely is reflected in increasing drug resistance,” said Dr Jason Burnham, of Washington University.

The CDC’s count is also only a partial picture. Many states are not fully testing and reporting cases. Even in states that do, cases tend to only be among hospital patients sick enough to warrant special testing.

The CDC researchers did not have data from some of the most populous states, including California, Florida, New York and Texas, which means the absolute number of US infections “is definitely underestimated,” Dr Burnham said.

Continue Reading

Trending